CNBC: Actavis swoops in on Allergan for Salix buyout talks

Talk about a love triangle. Actavis ($ACT) made an advance toward Allergan ($AGN) last month, which the latter spurned because it thought it was close to landing Salix ($SLXP). Now, sources tell CNBC that Actavis has swooped in on Salix, with deal talks ongoing. Report

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Disorder: The Rare Disease Film Festival is back and bigger than ever, set for a West Coast debut with 50 films this fall.